logo-loader
viewSareum Holdings PLC

Sareum raises £680k as it looks to take its TYK2/JAK1 inhibitors into the clinic next year

Sareum raised the money by selling 170.37mln new shares at 0.4p each – a 25% discount to Tuesday’s closing price

cytokine
TYK2/JAK1 inhibitors regulate the number of cytokines the body produces

Sareum Holdings PLC (LON:SAR) has raised £681,000 which it will use to advance its TYK2/JAK1 inhibitor programme towards human trials.

The drug developer sold 170.37mln new shares at 0.4p as part of the fundraising, which was carried out on the online investment platform, PrimaryBid.

Sareum has mapped out preclinical programmes for its two TYK2/JAK1 inhibitors – called SDC-1801 and SDC-1802 – and is targeting human trials at some point in 2020.

READ: Sareum surges as it signals progress on preclinical programmes

TYK2/JAK1 inhibitors work by regulating the number of cytokines – a group of proteins that play an important part in boosting the immune system – produced by the body.

They have proved useful in treating cancers such as renal cell carcinoma and melanoma, as well as autoimmune diseases such as psoriasis and alopecia.

“We are pleased to have successfully completed this new fundraising, particularly the participation from retail investors, as well as the continued support from our existing shareholder base,” said chief executive Tim Mitchell.

“The funds will be used to advance our lead internal TYK2/JAK1 inhibitor programmes towards human trials.

“We believe we have the potential to generate significant value with these candidates, which represent exciting prospects in an area of increasing interest in the pharmaceutical industry.”

Sareum shares fell 27% to 0.4p in early deals on Wednesday, reflecting the discount to the issue price.

Quick facts: Sareum Holdings PLC

Price: 0.425 GBX

AIM:SAR
Market: AIM
Market Cap: £13.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings says taking back control of cancer technology is “good news”

Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company took back the rights to Aurora +FLT3 kinase inhibitors from Hebei Medical University Biomedical Engineering Center in China. He said: “The initial project did seem to work very well, good progress...

on 1/6/18

2 min read